8-K: Intelligent Bio Solutions Completes In-Clinic Testing, Advances Towards FDA 510(k) Submission

Intelligent Bio Solutions has successfully completed in-clinic testing for its fingerprint-based drug screening system, a key step towards FDA 510(k) submission.

Summary

• Intelligent Bio Solutions Inc. has completed in-clinic testing for its clinical study plan, which was proposed to the FDA earlier this year.
• The clinical studies are crucial for the company's 510(k) submission, aiming to demonstrate the accuracy and reliability of their sweat-based testing method.
• A pharmacokinetic (PK) study was conducted to compare drug measurements in fingerprint sweat to other matrices like blood, saliva, and urine.
• A method comparison and usability study was also performed across three sites, involving 135 subjects who were tested using the company's drug screening system after being dosed with codeine.
• The company expects to complete clinical data analysis and submit the 510(k) package in the fourth calendar quarter of 2024.
• The company's fingerprint-based testing method aims to provide a non-invasive, reliable alternative to traditional drug testing methods.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of a key milestone in the FDA approval process. The company is progressing as expected and the technology has potential for market disruption.

Positives

• The successful completion of in-clinic testing is a significant milestone for the company.
• The company is progressing towards FDA 510(k) submission, which could lead to commercialization of their product.
• The fingerprint-based testing method has the potential to be a non-invasive and reliable alternative to traditional drug testing.
• The technology has potential applications in diverse sectors, including workplaces and government agencies.

Risks

• The company's ability to successfully develop and commercialize its drug and diagnostic tests is subject to risks and uncertainties.
• Securing regulatory approvals is not guaranteed and may be subject to delays.
• The company's expectations may prove to be materially different from the results expressed or implied by forward-looking statements.

Future Outlook

The company expects to complete clinical data analysis and submit the 510(k) package in the fourth calendar quarter of 2024. Achieving FDA clearance will enable the Company to market its product as a clinically validated tool.

Management Comments

• Daniel Brown, Head of Clinical Affairs at INBS, stated that executing these clinical studies required diligence and collaboration.
• Harry Simeonidis, President and CEO at INBS, said that completion of these in-clinic studies marks a significant achievement and brings them closer to obtaining FDA 510(k) clearance.
• Harry Simeonidis also noted that early feedback on results demonstrates the potential of their fingerprint-based testing method.

Industry Context

The announcement is relevant to the medical technology industry, particularly in the area of non-invasive drug testing. The company's technology could disrupt traditional drug testing methods and potentially gain market share in various sectors.

Comparison to Industry Standards

• The company's fingerprint sweat analysis technology is positioned as a non-invasive alternative to traditional methods like blood, saliva, and urine testing, which are common in the drug screening industry.
• Companies like Abbott and Roche offer various diagnostic testing solutions, but Intelligent Bio Solutions is focusing on a unique, non-invasive approach.
• The company's claim of rapid results in under ten minutes is competitive with other point-of-care testing solutions.

Stakeholder Impact

• Shareholders may view this progress positively as it increases the likelihood of product commercialization.
• Employees may be motivated by the company's progress and the potential for growth.
• Customers in various sectors may benefit from the non-invasive and rapid drug testing solution.
• Suppliers and partners may see increased business opportunities as the company moves closer to commercialization.

Next Steps

• The company will complete clinical data analysis.
• The company will submit the 510(k) package to the FDA.
• The company will prepare for the commercialization of its product upon FDA clearance.

Key Dates

Keywords

FDA 510(k), drug screening, fingerprint sweat analysis, non-invasive testing, clinical study, pharmacokinetic study, medical technology, regulatory approval